These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 29867106)
1. Epigenetics in renal cell cancer: mechanisms and clinical applications. Joosten SC; Smits KM; Aarts MJ; Melotte V; Koch A; Tjan-Heijnen VC; van Engeland M Nat Rev Urol; 2018 Jul; 15(7):430-451. PubMed ID: 29867106 [TBL] [Abstract][Full Text] [Related]
2. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750 [TBL] [Abstract][Full Text] [Related]
3. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493 [TBL] [Abstract][Full Text] [Related]
4. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299 [TBL] [Abstract][Full Text] [Related]
5. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001 [TBL] [Abstract][Full Text] [Related]
6. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836 [TBL] [Abstract][Full Text] [Related]
7. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan. Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766 [TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
10. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
11. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. Morris MR; Maina E; Morgan NV; Gentle D; Astuti D; Moch H; Kishida T; Yao M; Schraml P; Richards FM; Latif F; Maher ER J Clin Pathol; 2004 Jul; 57(7):706-11. PubMed ID: 15220362 [TBL] [Abstract][Full Text] [Related]
12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539 [TBL] [Abstract][Full Text] [Related]
15. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414 [TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinomas in trichloroethene (TRI) exposed persons are associated with somatic mutations in the von Hippel-Lindau (VHL) tumour suppressor gene. Brüning T; Weirich G; Hornauer MA; Höfler H; Brauch H Arch Toxicol; 1997; 71(5):332-5. PubMed ID: 9137812 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions. Goldsamt A; Damayanti NP; De Nigris F; Pili R Cancer J; 2020; 26(5):399-406. PubMed ID: 32947308 [TBL] [Abstract][Full Text] [Related]
18. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1). Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559 [TBL] [Abstract][Full Text] [Related]
19. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178 [TBL] [Abstract][Full Text] [Related]
20. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma. Mehdi A; Riazalhosseini Y Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]